Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changqing Su

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Oncotarget|June 28, 2014
Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal modelGaoya Xu, Weidan Ji, Yinghan Su, et al.
Molecular Cancer Research : MCR|March 18, 2008
Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacyChangqing Su, Manli Na, Jie Chen, et al.
Cancer Letters|May 21, 2013
MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathwaysLonglong Bao, Yan Yan, Can Xu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 16, 2008
Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primatesChangqing Su, Hui Cao, Shuping Tan, et al.
Oncotarget|December 5, 2014
Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse modelsHuanzhang Hu, Yinghe Qiu, Minggao Guo, et al.
Journal for Immunotherapy of Cancer|May 24, 2022
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumorsYinghan Su, Jiang Li, Weidan Ji, et al.
Cancer Letters|April 3, 2018
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinomaHaisen Yin, Risheng Que, Chunying Liu, et al.
Molecular Cancer Therapeutics|June 21, 2008
A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancersXinghua Wang, Changqing Su, Hui Cao, et al.
Molecular Cancer Therapeutics|June 6, 2008
Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkeyJie Chen, Changqing Su, Qiujun Lu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2006
Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent miceChangqing Su, Linhui Peng, Jonathan Sham, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Oncotarget|June 28, 2014
Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal modelGaoya Xu, Weidan Ji, Yinghan Su, et al.
Molecular Cancer Research : MCR|March 18, 2008
Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacyChangqing Su, Manli Na, Jie Chen, et al.
Cancer Letters|May 21, 2013
MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathwaysLonglong Bao, Yan Yan, Can Xu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 16, 2008
Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primatesChangqing Su, Hui Cao, Shuping Tan, et al.
Oncotarget|December 5, 2014
Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse modelsHuanzhang Hu, Yinghe Qiu, Minggao Guo, et al.
Journal for Immunotherapy of Cancer|May 24, 2022
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumorsYinghan Su, Jiang Li, Weidan Ji, et al.
Cancer Letters|April 3, 2018
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinomaHaisen Yin, Risheng Que, Chunying Liu, et al.
Molecular Cancer Therapeutics|June 21, 2008
A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancersXinghua Wang, Changqing Su, Hui Cao, et al.
Molecular Cancer Therapeutics|June 6, 2008
Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkeyJie Chen, Changqing Su, Qiujun Lu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2006
Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent miceChangqing Su, Linhui Peng, Jonathan Sham, et al.
Pageof 10